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Abstract
Yaws is a non-venereal treponemal infection caused by Treponema pallidum ssp. pertenue. The WHO has launched a
worldwide control programme, which aims to eradicate yaws by 2020. The development of a rapid diagnostic test (RDT) for
serological diagnosis in the isolated communities affected by yaws is a key requirement for the successful implementation
of the WHO strategy. We conducted a study to evaluate the utility of the DPP test in screening for yaws, utilizing samples
collected as part of a community prevalence survey conducted in the Solomon Islands. 415 serum samples were tested
using both traditional syphilis serology (TPPA and quantitative RPR) and the Chembio DPP Syphilis Screen and Confirm RDT.
We calculated the sensitivity and specificity of the RDT as compared to gold standard serology. The sensitivity of the RDT
against TPPA was 58.5% and the specificity was 97.6%. The sensitivity of the RDT against RPR was 41.7% and the specificity
was 95.2%. The sensitivity of the DPP was strongly related to the RPR titre with a sensitivity of 92.0% for an RPR titre of .1/
16. Wider access to DPP testing would improve our understanding of worldwide yaws case reporting and the test may play
a key role in assessing patients presenting with yaws like lesions in a post-mass drug administration (MDA) setting.
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Introduction
Yaws is a non-venereal treponemal infection caused by Trepo-
nema pallidum ssp. pertenue (T. pertenue) [1] which is currently
thought to be endemic in fourteen countries [2]. The emergence
of azithromycin as an effective oral agent in the treatment of yaws
[3] has prompted renewed calls for a coordinated worldwide
programme to eradicate the disease by 2020 [4].
Despite this optimism there are significant barriers still to be
overcome. The differential diagnosis of yaws can be broad [5] and
serological testing is necessary to help establish a diagnosis. As with
syphilis, latent infection occurs, and it is recognized that for every
clinical case there may be 5–6 individuals with serological
evidence of infection but no clinical manifestations [6,7]. Failure
to adequately treat latent cases was one of the reasons for the
failure of previous attempts to eliminate yaws [8]. Detection and
treatment of these latent cases will be extremely important if the
WHO eradication programme is to achieve its target.
Traditional syphilis serology includes a treponemal specific test,
such as the Treponema pallidum particle agglutination assay
(TPPA) or the fluorescent treponemal antibody test, and a non-
treponemal test, such as the Rapid Plasma Reagin (RPR) or
Venereal Disease Research Laboratory (VDRL) assays. The
former tests are highly specific but normally remain positive for
life following infection. The latter tests are non-specific but the
RPR titre more accurately reflects disease activity and falls
following successful treatment. Low-titre false-positive RPRs may
occur in a number of conditions including acute viral infections,
malaria and connective tissue diseases. Testing therefore requires
combined treponemal and non-treponemal assays to give a more
accurate diagnostic result.
The development of a rapid diagnostic test (RDT) that can be
used to improve access to serological diagnosis in the isolated
communities affected by yaws has been highlighted as a major
research question [9] to be addressed. RDTs allow wider access to
diagnostic testing in remote communities where laboratory
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facilities are not available, with results available at the point of
care to inform clinical decision making. As yaws is serologically
indistinguishable from syphilis [10], the recent development of
syphilis RDTs with high sensitivity and specificity [11] prompts
evaluation of their use for the diagnosis of endemic treponemal
diseases.
The required role(s) of an RDT may vary depending on the
progress of the eradication programme in a given country. The
test may have utility to confirm the diagnosis in patients presenting
with skin lesions, to detect ongoing transmission of infection after
mass drug administration has been conducted, or to conduct
community surveillance in areas previously known to be endemic.
The target product profiles of the RDTs required in each of these
settings are likely to vary.
The Dual Path Platform (DPP) Syphilis Screen and Confirm
(Chembio, Medford, NY, USA) provides both a ‘‘treponemal’’
result (analogous to a Treponema Pallidum Particle Agglutination
(TPPA) assay (T1 line)) and a ‘‘non-treponemal’’ result (analogous
to a qualitative Rapid Plasma Reagin (RPR) assay (T2 line)) [12].
We conducted a study to evaluate the utility of the DPP test in
screening for yaws in the general population, utilizing samples
collected as part of a community prevalence survey for yaws and
trachoma conducted in the Solomon Islands.
Methods
Participant Recruitment
This study was embedded in a larger study investigating the
epidemiology of yaws in the Solomon Islands. Briefly, we
undertook a survey in Western and Choiseul provinces of the
Solomon Islands in September and October 2013. Twenty-five
clusters were randomly selected in each province. In each cluster,
thirty households were visited, and children aged five to fourteen
were enrolled in the study. The study team collected information
on yaws symptoms, signs and treatment history. Venepuncture
was performed and a serum sample was collected from all
participants. Sera were kept on wet ice (4uC) in the field and
transferred within 5 days of collection to the National Referral
Hospital, Honiara, where they were frozen. Samples were shipped
on dry-ice to the London School of Hygiene & Tropical Medicine
(LSHTM).
Sample Size
We assumed that the prevalence of yaws sero-positivity by the
gold standard assay would be 30%. We therefore calculated that a
sample size of 415 was required to be 80% confident that the true
sensitivity of the DPP, compared to the gold standard, was 85% or
greater [13]. For the purposes of this study, simple random
sampling was used to select samples to undergo parallel testing
with both the DPP kit and traditional serology.
Laboratory Testing
Sera were tested using both the TPPA (Mast Diagnostics,
Merseyside UK) and a quantitative RPR (Deben Diagnostics,
Sheffield UK) at LSHTM by an operator masked to clinical
findings. A second operator, masked to clinical findings and gold
standard serology, tested samples using the DPP test kit. Samples
for which the control line did not appear were repeated. The
manufacturer’s instructions were followed for all test kits.
Statistical Analysis
The sensitivity, specificity, positive and negative predictive
values of the DPP test kit were calculated using traditional serology
as the gold standard. The DPP-T1 line was assessed against TPPA
and the DPP-T2 line was assessed against RPR. Secondary
analyses estimated these performance characteristics by RPR titre
and presence or absence of clinical signs of yaws. Confidence
intervals were calculated using robust standard errors to allow for
clustering. Findings are reported in line with the STARD checklist
for studies of diagnostic accuracy [14].
Ethics
Written, informed consent was obtained from the head of each
household, who was the parent or guardian of children enrolled in
Author Summary
Yaws is a bacterial infection closely related to syphilis. The
WHO has launched a worldwide campaign to eradicate
yaws by 2020. If this goal is to be achieved, programme
managers and clinical staff will need access to a rapid
diagnostic test (RDT) for yaws that can be used in the
remote communities where the disease is found. In this
study, we present data evaluating one possible RDT for
yaws as part of a community survey in the Solomon
Islands. The test performed reasonably well—there were
some false negatives but few false positives. The perfor-
mance of the test was best in individuals with more active
disease suggesting the test may be most appropriately
used for confirming clinically diagnosed cases. These
findings should prompt consideration of the use of this
RDT as part of worldwide yaws control efforts.
Table 1. Participant characteristics.
Number of children 415
Gender: Male(%) 216 (52.1%)
Age (yrs): Median (IQR) 9 (7–11)
Clinical signs of primary yaws 12 (2.9%)
Clinical signs of secondary yaws 7 (1.7%)
Clinical signs of healed yaws 34 (8.2%)
Recent treatment for yaws 54 (13.0%)
doi:10.1371/journal.pntd.0003156.t001
Figure 1. Clinical lesions of yaws. a) Primary yaws ulcer. b) Healed
yaws lesion. Images credit: Michael Marks.
doi:10.1371/journal.pntd.0003156.g001
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the study, and assent was obtained from all children. Ethical
approval for the study was granted by the ethics committees of the
Ministry of Health and Medical Services in the Solomon Islands,
and LSHTM in the UK.
Results
Participant Characteristics
Four hundred and fifteen samples were randomly selected. The
median age was 9, and 52.1% of participants were male.
Individuals selected for this study did not differ significantly from
the larger prevalence survey population with regards to demo-
graphic or clinical features (data not shown). Clinical findings
consistent with active and healed yaws were found in 19 (4.7%)
and 34 (8.2%) respectively of the 415 participants (Table 1 and
Figure 1).
Laboratory Testing
123 (29.6%) individuals had a reactive TPPA. 120 (28.9%)
individuals had a reactive RPR at any titre. By gold standard
serology there were 18 individuals with a false positive RPR
(defined as a positive RPR and negative TPPA). All false positive
RPRs in our study had an RPR titre of 1:2. The overall prevalence
of true RPR reactivity was therefore 102/415 (24.6%). The
distribution of RPR titres in the study population is given in
Figure 2.
79 individuals (19.0%) had a positive T1(treponemal) line on the
DPP kit. 64 (15.4%) individuals had a positive T2 (non-
treponemal) line on the DPP kit. There were ten individuals with
a positive T2 line but a negative T1 line. The overall prevalence of
dual-positivity was therefore 54/415 (13.0%).
The sensitivity of the T1 line against TPPA was 58.5% and the
specificity was 97.6%. The positive predictive value was 91.1%
and the negative predictive 84.5%. The sensitivity of the T2 line
against RPR was 41.7% and the specificity was 95.2%. The
positive predictive value was 78.1% and the negative predictive
value was 79.9%. The sensitivity of combined T1 and T2 against
combined TPPA and RPR was 47.1% and the specificity was
98.1%. The sensitivity of the DPP was strongly related to the RPR
titre (Tables 2 and 3)
In individuals with clinical signs of active yaws the sensitivity of
the T1 line, compared to TPPA, was 81.8% and the specificity was
100%. The sensitivity of the T2, compared to RPR, was 55.6%
and the specificity was 83.3%. A similar association was seen
between T2 sensitivity and RPR titre as in the overall population
(data not shown).
Discussion
In this study, we found that in a community surveillance setting,
the sensitivity and specificity of the DPP rapid diagnostic test were
markedly lower than in the only previous evaluation of the assay
for use in clinically active yaws [15]. There was a strong
association between the sensitivity of both the T2 line (against
gold standard RPR) and RPR titre and also between the T1 line
(against gold standard TPPA) and RPR titre. This finding might
suggest that the apparent reduced sensitivity of the test reflects, at
least in part, lower antibody titres in this population (where
positive serology predominantly reflected asymptomatic latent
cases) compared to populations in which the assay has previously
been evaluated (where there were greater numbers of patients with
active clinical disease), rather than a difference in test character-
istics per se. Despite the reduced sensitivity and specificity the
positive predictive values of the test remained relatively high,
reflecting the high prevalence of treponemal infection in this
endemic setting.
An association between the sensitivity of the T2 line and the
RPR titre has previously been noted [12], but an association
between RPR titre and T1 sensitivity has not been described
before. It is possible that, in keeping with its lower pathogenicity
compared to syphilis, yaws elicits less vigorous antibody produc-
tion than does its venereal cousin, affecting both the non-specific
(non-treponemal) and specific (treponemal) components of that
response. ‘Attenuated yaws’ has previously been described in the
Solomon Islands [16] with less florid clinical manifestations than
noted elsewhere. Widespread use of antibiotics with treponemo-
cidal activity has been postulated as one possible explanation for
Figure 2. RPR titre distribution.
doi:10.1371/journal.pntd.0003156.g002
Table 2. Test characteristics.
Positive by Gold
Standard DPP Sensitivity
DPP Positive
Predictive Value DPP Specificity
DPP Negative
Predictive Value
T1 (Treponemal Line) vs TPPA 123 58.5% (43.4–72.2%) 91.1% 97.6%(95.2–98.8%) 84.5%
T2 (Non-Treponemal Line) vs RPR 120 41.7% (28.0–56.8%) 95.2% 95.2%(92–95%) 79.9%
Dual Positive DPP (T1+T2) vs nDual
Positive Gold-Standard Serology
(TPPA+RPR)
102 47.1%(31.1–63.6%) 88.9% 98.1%(95.2–99.2%) 85.0%
doi:10.1371/journal.pntd.0003156.t002
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this postulated clinical entity. It is conceivable that this phenom-
enon could also contribute to the predominantly low-titre range of
antibody responses seen in this study.
The setting in which this evaluation was carried out varies
markedly from previous evaluations of the DPP test. In the largest
published study, which evaluated the test in the diagnosis of
syphilis, Yin and colleagues [11] evaluated the test in a population
of 1,323 individuals presenting to a sexual health clinic in China,
and found it to have a sensitivity of approximately 95% against
TPPA and 86% against RPR. An association between RPR titre
and sensitivity was also found in this study, although the
performance of the test was better at titres of 1:4 and 1:8 than
reported here.
Our study has a number of limitations. First, relatively few
individuals tested had clinical evidence of active yaws, reflecting
the community surveillance setting in which the test was evaluated.
Whilst this limits our ability to comment on the value of the test for
the purpose of case-confirmation, the aim of this study was to
evaluate the DPP’s use in screening whole communities at risk of
yaws, and for this context we provide the first published data.
Second, testing was performed in a central laboratory facility not
in the field. Although the test can be performed rapidly
(approximately 15–20 minutes per RDT), field-testing was not
practical alongside the other activities being performed in our
study, for which teams had to move house-to-house. Evaluations of
the test elsewhere show that test performance is unaffected by
whether venepuncture or finger-prick samples are used [11].
Further evaluations of the test in the field are warranted.
This study has implications for the use of the DPP RDT in yaws
surveillance and control. Whilst the sensitivity of the test was lower
than previously reported, the specificity remained high, and the
negative and positive predictive values of the test were also high.
Our data suggest that the DPP test can be used as part of a
community surveillance strategy to identify individuals who are
dually sero-positive with high-titre RPRs. These individuals are
most likely to represent the major source of ongoing transmission.
Identification of communities in which such individuals live is vital
to allow adequate community targeted treatment to be undertaken
[4]. The performance of the test in individuals with clinical
evidence of yaws was better than in those without clinical evidence
of disease, an association that is likely to be explained by the higher
RPR titres found in individuals with clinically active disease.
Because of inadequate access to point-of-care diagnostics, many
national yaws surveillance systems only report clinically suspected
cases. Wider access to DPP testing could allow a larger proportion
of these cases to be evaluated serologically, which would both
critically refine understanding of global yaws epidemiology as it
evolves towards the eradication endpoint, but also provide a vital
clinical aid in the post-MDA setting, where many conditions
mimicking yaws will continue to present to health-care facilities.
Further evaluation of the DPP in other yaws surveillance settings
would be welcomed to provide the basis for guideline develop-
ment.
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